Literature DB >> 19350342

A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis.

Giuseppe Paolazzi1, Susanna Peccatori, Francesco P Cavatorta, Alberto Morini.   

Abstract

We report the case of a 54-year-old patient affected by ankylosing spondylitis who developed multifocal motor neuropathy with conduction blocks after 8 months of infliximab treatment. TNF alpha antagonist therapy has been associated with the development of both central nervous system and peripheral nervous system disorders, mainly of the demyelinating type. To our knowledge, this seems to be the second reported case of infliximab-related typical multifocal motor neuropathy with conduction blocks in which no other underlying causes of neuropathy were present. It is also the first in which typical multifocal motor neuropathy with conduction blocks spontaneously recovered without Ig.ev treatment and did not reappear over a long follow-up period. In our opinion, this strengthens the hypothesis of an actual adverse effect of infliximab in this patient. Finally, our case is the first one occurring in a patient with ankylosing spondylitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19350342     DOI: 10.1007/s10067-009-1174-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

1.  Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy.

Authors:  C Rodriguez-Escalera; J Belzunegui; L Lopez-Dominguez; C Gonzalez; M Figueroa
Journal:  Rheumatology (Oxford)       Date:  2005-01       Impact factor: 7.580

2.  Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy.

Authors:  Oliver C Singer; Bettina Otto; Helmuth Steinmetz; Ulf Ziemann
Journal:  Neurology       Date:  2004-11-09       Impact factor: 9.910

3.  Multifocal motor neuropathy during treatment with infliximab.

Authors:  Dario Cocito; Bruno Bergamasco; Alessia Tavella; Fabio Poglio; Ilaria Paolasso; Paolo Costa; Palma Ciaramitaro; Gianluca Isoardo
Journal:  J Peripher Nerv Syst       Date:  2005-12       Impact factor: 3.494

4.  Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.

Authors:  Maria G Tektonidou; John Serelis; Fotini N Skopouli
Journal:  Clin Rheumatol       Date:  2006-07-06       Impact factor: 2.980

5.  Infliximab-associated neuropathy in RA patients--the importance of considering the diagnosis of mononeuritis multiplex.

Authors:  J Birnbaum
Journal:  Clin Rheumatol       Date:  2006-10-25       Impact factor: 2.980

6.  Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis.

Authors:  Przemyslaw J Kotyla; Bogna Sliwinska-Kotyla; Eugene J Kucharz
Journal:  Clin Rheumatol       Date:  2007-06-05       Impact factor: 2.980

7.  Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.

Authors:  Laurence Fardet; Alain Dupuy; Delphine Kerob; Annabelle Levy; Matthieu Allez; Edouard Begon; Hervé Bachelez; Patrice Morel; Celeste Lebbé
Journal:  J Am Acad Dermatol       Date:  2007-01-22       Impact factor: 11.527

Review 8.  Multifocal motor neuropathy: current concepts and controversies.

Authors:  Eduardo Nobile-Orazio; Alberto Cappellari; Alberto Priori
Journal:  Muscle Nerve       Date:  2005-06       Impact factor: 3.217

9.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

Review 10.  Tumor necrosis factor-alpha antagonists and neuropathy.

Authors:  Joerg-Patrick Stübgen
Journal:  Muscle Nerve       Date:  2008-03       Impact factor: 3.217

  10 in total
  3 in total

1.  Isolated motor conduction block associated with infliximab.

Authors:  A W Michell; A Gaitatzis; J Burge; M M Reilly; R Kapoor; M Koltzenburg
Journal:  J Neurol       Date:  2012-02-18       Impact factor: 4.849

Review 2.  Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects.

Authors:  Christie M Lincoln; Peter Fata; Susan Sotardi; Michael Pohlen; Tomas Uribe; Jacqueline A Bello
Journal:  Br J Radiol       Date:  2017-11-03       Impact factor: 3.039

3.  Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.

Authors:  Julius Birnbaum; Clifton O Bingham
Journal:  Semin Arthritis Rheum       Date:  2013-10-30       Impact factor: 5.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.